Date | 27 January 2021 (mass vaccination started on 7 Feb 2021)[1][2] | – present
---|---|
Location | Bangladesh |
Cause | COVID-19 pandemic |
Target | Immunization against COVID-19 |
Budget | ৳14,000 Crore (US$1.68 billion) |
Organized by | DGHS MoHFW ICDDR DGDA |
Participants | 81,648,954 people have registered for vaccination and a total of 141,479,208 doses of vaccine have been administered so far of which 85,287,956 people with at least one dose administered of Pfizer–BioNTech, Moderna, Oxford–AstraZeneca, Sinopharm BIBP or Sinovac 56,191,252 people fully vaccinated [3] |
Website | Surokkha |
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.[1][2]
The Oxford–AstraZeneca vaccine was the only COVID-19 vaccine authorized for emergency use from January to April 2021. Bangladesh ordered vaccines produced by Serum Institute of India; however, it delivered to Bangladesh less than half of the doses that had been agreed.[5] After the consequent vaccine shortage, Bangladesh approved the Russian Sputnik V and Chinese Sinopharm BIBP vaccines for emergency use in late April 2021.[6][7] Bangladesh also authorized the emergency use of Pfizer–BioNTech COVID-19 vaccine to be distributed as part of COVAX. It was reported that the Bangladesh government planned to give permission to Bangladeshi-made Bangavax developed by Globe Biotech Ltd.[8] to conduct the first clinical trial that got listed in the 'Draft landscape and tracker of Covid-19 candidate vaccines'[9] by the World Health Organization (WHO).[10] However, the fate of Bangavax is still uncertain due to an unknown reason.[11] Less than 4% of Bangladesh's population had gotten two doses as of the beginning of June 2021. Bangladesh has already fully immunized more than 70% of its population and received funding from a program called Friendship. [12][13]
As of October 2021, Bangladesh has fully approved 7 COVID-19 vaccines.